On April 22–23, 2026, the 7th BIONNOVA Biopharmaceutical Innovators Forum & Expo will be held at Zhangjiang Science Hall in Shanghai. The event will feature a comprehensive program including keynote speeches, panel discussions, technology-focused sessions, BIONNOVA Awards, investment and financing roadshows, one-on-one partnering meetings, and BIONNOVA Fun interactive activities. These diverse formats are designed to help attendees gain insights into cutting-edge research while exploring collaboration opportunities in a practical and engaging environment.

Dr. Michael Chen, Co-founder and CEO of Great Bay Bio, will deliver a presentation at the Antibody Drug Development Breakthrough Forum from 11:15–11:40 AM on April 22, titled “Advancing AI-Driven Biopharmaceuticals Toward Engineering and Commercialization: New Value of Fluorescent Site-Specific Integration Cell Platforms.”

Dr. Chen will share how Great Bay Bio leverages AI and site-specific integration technologies to empower biopharmaceutical CMC development. Key achievements include the rapid generation of high-titer, stable cell lines within 1.5 months, early prediction of product quality within 1 month, and average expression levels exceeding 6.9 g/L across client projects. These innovations effectively address process development challenges for complex biologics such as bispecific antibodies and ADCs, significantly shorten IND timelines and regulatory submission processes, and accelerate the transition of client programs toward engineering and commercialization.

Great Bay Bio sincerely invites you to join us onsite for discussion and collaboration.